var data={"title":"Human papillomavirus quadrivalent vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Human papillomavirus quadrivalent vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/228154?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Human papillomavirus quadrivalent vaccine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Human papillomavirus quadrivalent vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5994263\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gardasil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000506\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000566\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Prevention of human papillomavirus infection:</b> IM: Adults: Females &le;45 years of age and males &le;26 years of age: Three-dose series: 0.5 mL at 0, 2, and 6 months. Administer the second dose &ge;1 month after the first dose and the third dose &ge;3 months after the second dose; administer all 3 doses within 12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>NACI recommendations: </i>Recommended for females and males &le;26 years of age; may be given to those &ge;27 years of age who are at ongoing risk (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3001516\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Human papillomavirus quadrivalent vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Prevention of human papillomavirus infection:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 14 years: Minimum interval between first and last dose is 6 months. For immunocompromised patients, the 3-dose series is recommended (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2-dose series: 0.5 mL at 0 and 6 to 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3-dose series: Alternative dosage regimen: 0.5 mL at 0, 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;15 years of age: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22125141\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22125142\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000504\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50966562\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection, suspension [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gardasil: HPV 6 L1 protein 20 mcg, HPV 11 L1 protein 40 mcg, HPV 16 L1 protein 40 mcg, and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL) [contains aluminum, polysorbate 80; manufactured using <i>S. cerevisiae</i> (yeast)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3001517\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Shake suspension well before use. Inject the entire dose IM into the deltoid region of the upper arm or higher anterolateral thigh area. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down. When given with other age appropriate vaccines, human papillomavirus vaccine should be given after other vaccines because it may cause more pain with injection (NACI 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for 5 to 10 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000508\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of human papillomavirus infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females &ge;9 years of age and &le;26 years of age: Prevention of anal cancer caused by HPV types 16 and 18; anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females &ge;9 years of age and &le;45 years of age: Prevention of cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma <i>in situ</i>, vulvar, vaginal, or cervical intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males &ge;9 years of age and &le;26 years of age: Prevention of anal cancer caused by HPV types 16 and 18; anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18; genital warts caused by HPV types 6 and 11</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Canadian National Advisory Committee on Immunization (NACI) recommends routine vaccination for females and males between 9 and 26 years of age. It should not be administered in patients &lt;9 years of age but may be administered to patients &gt;26 years of age who are at ongoing risk of exposure (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9518288\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil) may be confused with Papillomavirus vaccine types 16, 18 (Cervarix)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil) may be confused with Papillomavirus vaccine 9-valent (Gardasil 9)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine) may be confused with IPV (inactivated poliovirus vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine) may be confused with HBV (previously used for hepatitis B vaccine; HepB is correct abbreviation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine) may be confused with Hib (<i>Haemophilus</i> b conjugate vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV4 (human papillomavirus vaccine [quadrivalent]) may be confused with HepA (hepatitis A vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV4 (human papillomavirus vaccine [quadrivalent]) may be confused with HepB (hepatitis B vaccine)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000556\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (8% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (females: 82%; males: 61%), swelling at injection site (females: 24%; males: 14%), erythema at injection site (17% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Injection site pruritus (females: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (2% to 4%), diarrhea (males: 3%), toothache (females: 2%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hematoma at injection site (females: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (females: 2% to 3%), arthralgia (&le;1%), myalgia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (males: 3%), upper respiratory tract infection (males: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute disseminated encephalomyelitis, anaphylactoid reaction, anaphylaxis, arthropathy (impaired joint movement at injection site), asthma, autoimmune disease, autoimmune hemolytic anemia, bronchospasm, cellulitis, chills, fatigue, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, immune thrombocytopenia, lymphadenopathy, malaise, neuromuscular disease, pancreatitis, paralysis, pulmonary embolism, syncope (may result in falls or be associated with tonic-clonic movements), transverse myelitis, urticaria, weakness seizure, sepsis, syncope (may result in falls with injury or be associated with tonic-clonic movements), transverse myelitis, urticaria, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000514\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the vaccine or to a previous dose of the vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000553\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human papillomavirus (HPV) infection: There is no evidence that individuals already infected with HPV will be protected; those already infected with 1 or more HPV types were protected from disease in the remaining HPV types. Not for the treatment of active disease; will not protect against diseases not caused by HPV vaccine types 6, 11, 16, and 18.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) is recommended of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The NACI prefers each dose in a HPV vaccine series be the same vaccine when possible; however, if the previous vaccine is not known then any of the HPV vaccines licensed for use in Canada may be used. (<b>Note:</b> The HPV2 vaccine only protects again HPV types 16 and 18 and is not approved for use in males.) (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: May be administered to those who are immunosuppressed. Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high dose corticosteroids]); may have a reduced response to vaccination (NACI 2017). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Yeast: Product may contain yeast.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maximum efficacy: The entire 3-dose regimen should be completed for maximum efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299822\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000561\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9054&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000510\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Administration of the human papillomavirus vaccine during pregnancy is not recommended. Although exposure to human papillomavirus vaccine has not been causally associated with adverse pregnancy outcomes, until additional information is available the vaccine series (or completion of the series) should be delayed until pregnancy is completed (NACI 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommend pregnancy be avoided during the vaccination series.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Exposures to quadrivalent human papillomavirus vaccine during pregnancy should be reported to the manufacturer (800-267-2594) or Vaccine Safety Section at Public Health Agency of Canada (866-844-0018 or http://www.phac-aspc.gc.ca/im/vssv/index-eng.php).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000513\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if this vaccine is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breastfeeding women may receive the human papillomavirus vaccine if otherwise indicated. Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3001519\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Screening for HPV is not required prior to vaccination. Monitor for anaphylaxis and syncope for 15 minutes following administration (NACI 2017). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females: Gynecologic screening exam, papillomavirus test; screening for cervical cancer should continue per current guidelines following vaccination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3001513\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contains inactive human papillomavirus (HPV) proteins HPV 6 L1, HPV 11 L1, HPV 16 L1, and HPV 18 L1 which produce neutralizing antibodies to prevent cervical cancer, cervical adenocarcinoma, cervical, vaginal and vulvar neoplasia, and genital warts caused by HPV. The vaccine has not been shown to provide cross-protective efficacy to HPV types not contained in the vaccine. Immunogenicity has been measured by the percentage of persons who became seropositive for antibodies contained in the vaccine; the minimum anti-HPV antibody concentration needed to protect against disease has not been determined. The population benefit to vaccination is influenced by the prevalence of HPV within the geographic area and subject characteristics (eg, lifetime sexual partners).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efficacy: In females 16 to 26 years of age, HPV4 has shown to be ~100% effective against HPV types 16- and 18-related cervical disease and 95% to 99% effective against external genital lesions related to HPV types 6, 11, 16, or 18. In males 16 to 26 years of age, HPV4 vaccine has shown to be 84% to 100% effective against external genital lesions related to HPV types 6, 11, 16, or 18. In females 24 to 45 years of age, the vaccine was shown to be 91% effective against HPV 6, 11, 16, and 18 persistent infection and cervical or external genital disease and 83% effective against HPV types 16 and 18 only. In addition, vaccination against HPV types 16 and 18 may prevent ~70% of anogenital cancers and 60% of high-risk precancerous cervical lesions (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559927\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Seroconversion was observed 1 month following the last dose of vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Duration unknown. Clinical studies followed HPV4 vaccinated participants for 10 years and found no evidence of waning protection (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038887\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gardasil (AE, AR, AT, AU, BE, BG, BH, CH, CL, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JP, KR, KW, LB, LT, LU, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SK, SV, TH, TR, TW, UA, UY, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI) 2017. https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FUTURE II Study Group, &ldquo;Quadrivalent Vaccine Against Human Papillomavirus to Prevent High-Grade Cervical Lesions,&rdquo; <i>N Engl J Med</i>, 2007, 356(19):1915-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/17494925/pubmed\" target=\"_blank\" id=\"17494925\">17494925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardasil [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garland SM, Hernandez-Avila M, Wheeler CM, et al, &ldquo;Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases,&rdquo; <i>N Engl J Med</i>, 2007, 356(19):1928-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/17494926/pubmed\" target=\"_blank\" id=\"17494926\">17494926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giuliano AR, Palefsky JM, Goldstone S, et al, &ldquo;Efficacy of Quadrivalent HPV Vaccine Against HPV Infection and Disease in Males,&rdquo; <i>N Eng J Med</i>, 2011, 364(5):401-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutsky LA, Ault KA, Wheeler CM, et al, &ldquo;A Controlled Trial of a Human Papillomavirus Type 16 Vaccine,&rdquo; <i>N Engl J Med</i>, 2002, 347(21):1645-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/12444178/pubmed\" target=\"_blank\" id=\"12444178\">12444178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mao C, Koutsky LA, Ault KA, et al, &ldquo;Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial,&rdquo; <i>Obstet Gynecol</i>, 2006, 107(1):18-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/16394035/pubmed\" target=\"_blank\" id=\"16394035\">16394035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mu&ntilde;oz N, Manalastas R Jr, Pitisuttithum P, et al, &ldquo;Safety, Immunogenicity, and Efficacy of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in Women Aged 24-45 Years: A Randomised, Double-Blind Trial,&rdquo; <i>Lancet</i>, 2009, 373(9679):1949-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/19493565/pubmed\" target=\"_blank\" id=\"19493565\">19493565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Advisory Committee on Immunization (NACI), &ldquo;Statement on Human Papillomavirus Vaccine. An Advisory Committee Statement (ACS),&rdquo; Can Commun Dis Rep, 2007, 33(ACS-2):1-31.https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html17520773</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Advisory Committee on Immunization (NACI); Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian Immunization Guide. Public Health Agency of Canada website. http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php. Accessed January 9, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petrosky E, Bocchini JA, Hariri S, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):300-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/25811679/pubmed\" target=\"_blank\" id=\"25811679\">25811679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reisinger KS, Block SL, Collins-Ogle M, et al, &ldquo;Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel,&rdquo; <i>Pediatrics</i>, 2010, 125(6):1142-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/20439595/pubmed\" target=\"_blank\" id=\"20439595\">20439595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saslow D, Castle PE, Cox JT, et al, &ldquo;American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors,&rdquo; <i>CA Cancer J Clin</i>, 2007, 57(1):7-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/17237032 /pubmed\" target=\"_blank\" id=\"17237032 \">17237032 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinbrook R, &ldquo;The Potential of Human Papillomavirus Vaccines,&rdquo; <i>N Engl J Med</i>, 2006, 354(11):1109-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/16540608/pubmed\" target=\"_blank\" id=\"16540608\">16540608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vesikari T, Van Damme P, Lindblad N, et al, &ldquo;An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine Given Concomitantly With Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 17 Years of Age,&rdquo; <i>Pediatr Infect Dis J</i>, 2010, 29(4):314-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-drug-information/abstract-text/19952980/pubmed\" target=\"_blank\" id=\"19952980\">19952980</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9054 Version 115.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5994263\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3000506\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3000566\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F3001516\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22125141\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22125142\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3000504\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50966562\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3001517\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3000508\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9518288\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3000556\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3000514\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3000553\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299822\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3000561\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3000510\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3000513\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3001519\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3001513\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9559927\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038887\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9054|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-patient-drug-information\" class=\"drug drug_patient\">Human papillomavirus quadrivalent vaccine: Patient drug information</a></li><li><a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Human papillomavirus quadrivalent vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}